Put companies on watchlist
Sartorius Stedim Biotech SA
ISIN: FR0013154002
WKN: A2AJKS
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Sartorius Stedim Biotech SA · ISIN: FR0013154002 · EQS - Company News (4 News)
Country: France · Primary market: France · EQS NID: 2086777
17 February 2025 10:02AM

Sartorius Stedim Biotech releases Universal Registration Document 2024


Sartorius Stedim Biotech SA / Key word(s): Annual Results
Sartorius Stedim Biotech releases Universal Registration Document 2024

17-Feb-2025 / 10:02 CET/CEST


Aubagne, France | February 17, 2025

Sartorius Stedim Biotech releases Universal Registration Document 2024

Sartorius Stedim Biotech, a leading partner of the biopharma industry, today released its Universal Registration Document 2024 including the Annual Financial Report. The document is available at the following link: https://ir-reports.sartorius.com/en/ssb/fy-2024/



Financial calendar 
March 25, 2025               Annual Shareholders’ Meeting  
April 16, 2025                 Publication of the first quarter results January to March 2025  
July 22, 2025                  Publication of the half-year results January to June 2025 
October 16, 2025           Publication of the nine-month results January to September 2025 


A profile of Sartorius Stedim Biotech 
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros. Currently, more than 9,900 employees are working for customers around the globe.  
 
Visit our Newsroom and follow us on LinkedIn 


Contact
Leona Malorny
Head of External Communications
+49 551 308 4067
leona.malorny@sartorius.com
 


Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


Language: English
Issuer: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone: +33 44 284 5600
E-mail: sartorius.presse@sartorius.com
Internet: www.sartorius-stedim.com
ISIN: FR0013154002
EQS News ID: 2086777

 
End of Announcement - EQS News Service

2086777  17-Feb-2025 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2086777&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Sartorius Stedim Biotech SA
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.